vaccine under the brand name „HNVAC™. HNVAC™ is the only developing world flu vaccine to be manufactured in cell culture, a highly sterile and controlled manufacturing process, instead of eggs. HNVAC™ was tested extensively in one of the largest Phase I, II and III clinical trials for flu
vaccines in India and has proved that it is safe and well tolerated. Making the announcement Bharat Biotech?s Chairman and Managing Director, Dr. Krishna Ella, said we are pleased to announce the launch of HNVAC™ to help prevent the spread of H1N1 pandemic influenza, which can spread rapidly with a high rate of disease and death. Bharat Biotech is proud to develop and offer this vaccine with the best USFDA recommended cell culture technology for Indian consumers. While there?s certainly widespread and growing concern around H1N1, there are number of people who did not get a flu shot last year. Our goal right now is get the flu vaccine easily accessible and at affordable cost to high risk groups he
added.
“The key benefit of our cell culture vaccine is its potential to scale up and produce large
quantities quickly as required, it also has a much more sterile and faster production cycle, without
the external dependence on eggs and thus enabling quicker response times in the event of a
pandemic. We?ll also explore ways in which Bharat Biotech can assist consumers and
government agencies throughout this and subsequent flu season to get HNVAC™ flu shot,” Dr.
Ella added. Bharat Biotech?s goal is to develop world class technologies and offer them to the
Indian population and for emerging markets. We are proud to offer this technology to global
populations.
